New Study Results Show That Patients Have Higher Treatment Satisfaction With Liraglutide Compared To

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
23rd October 2009, 08:36am - Views: 658





Community Health Novo Nordisk 1 image

Community Health Novo Nordisk 2 image










MEDIA RELEASE PR36724


New Study Results Show That Patients Have Higher Treatment Satisfaction With

Liraglutide Compared to Exenatide


MONTREAL, Oct. 23 /PRNewswire-AsiaNet/ --


    New data on patient treatment satisfaction from the LEAD(TM) 6 trial 

presented on the 22nd October at the 20th World Diabetes Congress 

(International Diabetes Federation) shows that patients have higher overall 

treatment satisfaction with liraglutide than they do with exenatide.[1]


    To view the Multimedia News Release, please click:




    Specifically, among the 379 patients who completed the Diabetes Treatment

Satisfaction Questionnaires (DTSQ) during the LEAD(TM) 6 trial, those taking

liraglutide perceived less hypoglycaemia (abnormally low blood sugar levels)

or hyperglycaemia (abnormally high blood sugar levels) compared to those on

exenatide.[1]


    "Liraglutide has shown here in a convincing study that it is associated

with less nausea, less perceived hypoglycaemia and definitely higher patient

satisfaction compared to exenatide," said Dr Wolfgang Schmidt, professor and

chair of the Department of Medicine at St. Josef-Hospital and one of the

principal investigators in the trial.


    "Patient-reported outcomes data is an important extension of the efficacy

data. If a patient is satisfied with his or her treatment, then they are much

more likely to really stick to the treatment over the long term, which is

necessary in type 2 diabetes," Dr Schmidt noted.


    Treatment satisfaction was also evaluated during an open-label extension

of the LEAD(TM) 6 trial, in which patients were either switched from

exenatide to liraglutide or continued on liraglutide for another 14 weeks.

These results show that switching patients from exenatide to liraglutide

further improves patient satisfaction, as evidenced by the larger rise in

DTSQs scores for switched patients compared to those who continued on

liraglutide from weeks 26-40.


    Other key liraglutide data at IDF Congress


    Two separate meta-analyses of all six LEAD(TM) (Liraglutide Effect and

Action in Diabetes) trials were also presented at the congress. Meta-analyses

are a type of statistical analysis that summarise the results for a given

treatment from several different studies in order to evaluate its overall

effect on a specific outcome.


    The meta-analyses presented at the congress documented:


    1) Liraglutide's positive effect on lipid profile in patients with type 2

diabetes[2] and 2) liraglutide's ability to lower both HbA1C and weight

without inducing hypoglycaemia versus that of the other active comparators in

the LEAD(TM) programme including exenatide, glimepiride, rosiglitazone and

insulin glargine.[3] Each of the meta-analyses comprised 3,967 people with

type 2 diabetes.


    In the lipid meta-analysis, total cholesterol, low density lipoprotein,

free fatty acids and triglycerides were all statistically significantly

reduced from baseline with liraglutide over 26 weeks of treatment.

Furthermore, total cholesterol and low density lipoproteins were

significantly reduced with liraglutide treatment compared to rosiglitazone,

glimepiride or insulin glargine.[2]


    In the meta-analysis evaluating efficacy on combined treatment targets of

HbA1c and weight without hypoglycaemia, more patients in the liraglutide

group reached HbA1c<7.0% with no weight gain or hypoglycaemia than those on

comparator treatments. Patients were more likely to reach these treatment

goals without hypoglycaemia on liraglutide compared to other commonly used

diabetes treatments.[3]


    LEAD(TM) 6 trial, extension and sub-analysis designs


    LEAD(TM) 6 was a 26-week, open-label trial of 464 patients with type 2

diabetes and HbA1c levels between 7-11%, who were randomised to once-daily

liraglutide or twice-daily exenatide on a metformin plus or minus

sulphonylurea therapy background. Results from this direct comparison trial

were published in The Lancet.[4]


    In the LEAD(TM) 6 extension trial, patients were either switched from

exenatide to liraglutide or continued on liraglutide for a period of 14

weeks. All 389 patients who completed the randomised trial entered into the

extension phase.[5]


    In the patient-reported outcomes analysis, a subgroup of 379 patients had

treatment satisfaction evaluated using two versions of the Diabetes Treatment

Satisfaction Questionnaire: status (DTSQs) at baseline and week 26, and

change (DTSQc) at week 26. Patients had higher overall treatment satisfaction

with liraglutide than they did with exenatide and, in particular, their

perception of hyperglycaemia and hypoglycaemia was reduced more by

liraglutide than by exenatide.


    In the 14-week extension, 313 patients answered the DTSQs at weeks 34 and

40 and the DTSQc at week 34. These results showed that switching patients

from exenatide to liraglutide further improves patient satisfaction, as

evidenced by the larger rise in treatment satisfaction scores for switched

patients compared to those who continued on liraglutide from weeks 26-40.[1]


    About Victoza(R)


    Victoza(R) is a human glucagon-like peptide-1 (GLP-1) analogue developed

for the treatment of type 2 diabetes. Victoza(R) lowers blood glucose by

stimulating the release of insulin when blood sugar levels are high and also

by slowing gastric emptying. Victoza(R) also reduces body weight and body fat

mass through mechanisms involving reduced hunger and lowered energy intake.


    The European Commission granted marketing authorisation for Victoza(R) on

30 June 2009 for all 27 European Union member states and it is already on the

market in Germany, the UK and Denmark. According to this authorisation,

Victoza(R) is indicated for the treatment of adults with type 2 diabetes

mellitus to achieve glycaemic control:

    

    - in combination with metformin or a sulphonylurea in patients with

insufficient glycaemic control despite maximal tolerated dose of monotherapy

with metformin or sulphonylurea, and


    - in combination with metformin and a sulphonylurea or metformin and a

thiazolidinedione in patients with insufficient glycaemic control despite

dual therapy.


Community Health Novo Nordisk 3 image

    Multimedia press release:


    To view an online version of this press release, including video comments

from Dr Wolfgang Schmidt, Professor of Medicine, St Josef Hospital

Ruhr-Bochum University, Germany, Dr Bernard Zinman, Director, Leadership

Sinai Centre for Diabetes, Professor of Medicine, University of Toronto,

Canada and Dr Mads Krogsgaard Thomsen, Chief Science Officer, Novo Nordisk,



    For more information on Victoza(R), please visit



    Novo Nordisk is a healthcare company and a world leader in diabetes care.

In addition, Novo Nordisk has a leading position within areas such as

haemostasis management, growth hormone therapy and hormone replacement

therapy. Novo Nordisk manufactures and markets pharmaceutical products and

services that make a significant difference to patients, the medical

profession and society. With headquarters in Denmark, Novo Nordisk employs

approximately 28,500 employees in 81 countries, and markets its products in

179 countries. Novo Nordisk's B shares are listed on the stock exchanges in

Copenhagen and London. Its ADRs are listed on the New York Stock Exchange

under the symbol 'NVO'. For more information, 



        

    References


    ---------------------------------


    [1] Christiansen et al. Improved patient-reported outcomes following

treatment for type 2 diabetes with liraglutide compared with exenatide, in

addition to metformin, sulphonylurea or both, 20th World Diabetes Congress

18-22 Oct 2009, Montreal, CAN; Abstract P-1403.


    [2] Plutzky et al. Reductions in lipids and CV risk markers in T2D

patients treated with liraglutide: a meta-analysis. 20th World Diabetes

Congress 18-22 Oct 2009, Montreal, CAN; Abstract O-0542.


    [3] Zinman et al. Impact of liraglutide on reaching target HbA1C without

weight gain or hypoglycaemia, versus other T2D therapies. 20th World Diabetes

Congress 18-22 Oct 2009, Montreal, CAN; Abstract D-0910.


    [4] Buse J et al. A switch from twice-daily exenatide to once-daily

liraglutide further improves glycaemic control in patients with type 2

diabetes on oral patients. Diabetologia 2009; 52 (Suppl. 1): Abstract 2.


    [5] Buse J, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett J,

Zychma M, Blonde L for the LEAD 6 study group. Liraglutide once a day versus

exenatide twice a day for type 2 diabetes: a 26-week randomised,

parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374

(9683): 39-47.


    SOURCE: Novo Nordisk


To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article